Cover Image

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany

An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). Chemonaïve and pretreated patients with inoperable MM of the pleura or peritoneum were eligible. This report describes the resu...

Full description

Saved in:
Bibliographic Details
Main Authors: Reck, Martin (Author) , Stahel, Rolf A. (Author) , von Pawel, Joachim (Author) , Karthaus, Meinolf (Author) , Korfee, Soenke (Author) , Serke, Monika (Author) , Schuette, Wolfgang H. -W. (Author) , Eschbach, Corinna (Author) , Fink, Thomas H. (Author) , Leschinger, Monika I. (Author) , Manegold, Christian (Author)
Format: Article (Journal)
Language:English
Published: January 2010
In: Respiratory medicine
Year: 2010, Volume: 104, Issue: 1, Pages: 142-148
ISSN:1532-3064
DOI:10.1016/j.rmed.2009.07.019
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.rmed.2009.07.019
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0954611109002790
Get full text
Author Notes:Martin Reck, Rolf A. Stahel, Joachim von Pawel, Meinolf Karthaus, Soenke Korfee, Monika Serke, Wolfgang H.-W. Schuette, Corinna Eschbach, Thomas H. Fink, Monika I. Leschinger, Christian Manegold
Description
Summary:An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). Chemonaïve and pretreated patients with inoperable MM of the pleura or peritoneum were eligible. This report describes the results obtained in German centers. Investigators could choose between three treatments: Pemetrexed 500mg/m2 alone (P) or in combination with cisplatin 75mg/m2 (PC) or carboplatin AUC 5 (PCb). From November 2002 to June 2004, a total of 567 patients (554 with pleural MM; 41% pretreated) were included. Of 548 evaluable patients with pleural MM, 191 received P, 137 PC and 220 PCb. Patients in the P group were more often pretreated (70%) and had worse performance status compared with the other groups. In the P, PC, and PCb groups overall response rate (ORR) was 16%, 24% and 18%, median time to progression (TTP) was 5.5, 8.2, and 6.9 months, and median overall survival (OS) was 8.7, 11.3 and 9.7 months respectively. Efficacy outcomes were better for chemonaïve than for pretreated patients, and P was less hematotoxic than PC or PCb. Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy.
Item Description:Online verfügbar: 8. Oktober 2009
Gesehen am 11.05.2023
Physical Description:Online Resource
ISSN:1532-3064
DOI:10.1016/j.rmed.2009.07.019

Similar Items